ZVSA: חוב לטווח קצר של החברה ZyVersa Therapeutics Inc.

ZyVersa Therapeutics (ZVSA) relies on a compact staff of leading clinicians, where an academic atmosphere and RSU-based incentives replace corporate bureaucracy. The price indicator on the chart confirms its status as a scientific leader in the therapy of inflammatory kidney pathologies, with the current metric standing at 0.00. Thanks to an autonomous development cycle, the business remains shielded from macroeconomic shocks, ensuring stable growth through unique medical innovations.

ZyVersa Therapeutics (ZVSA) focuses on developing innovative kidney therapies, leveraging robust patent protection and a complete absence of borrowed funds. This short-term debt profile captures the aggregate of all liabilities maturing within one year, confirming zero leverage and eliminating liquidity gap risks, which significantly reduces the company's cost of capital.